Antibe Therapeutics: Top 10 Undervalued Nano Cap Stocks on TSX (ATE)
Antibe Therapeutics is now ranked among the top 10 nano cap stocks on the Toronto Stock Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below). Nano caps total market capitalization (<50M).
All data provided as-at market close February 02, 2023. The list is sorted by stocks with the greatest percentage difference between valuation and price. Antibe Therapeutics Antibe Therapeutics Inc is a healthcare company. It is engaged in the development of patents and out-licensing of improved compounds of existing drugs. The company has two primary business segments: Antibe Therapeutics and Citagenix. Antibe Therapeutics is listed under ATE on the Toronto Stock Exchange.
| Symbol | Name | Close Price | Shares Outstanding | P/E | P/B | Cash per Share | Net Cash per Share |
|---|---|---|---|---|---|---|---|
| ATE-T | Antibe Therapeutics | 0.59 | 0 | 0 | 0 | 0 | 0 |
| ELEF-T | Silver Elephant Mining | 0.47 | 0 | 0 | 0 | 0 | 0 |
| FLNT-T | FLINT | 0.04 | 0 | 0 | 0 | 0 | 0 |
| XLY-T | Auxly Cannabis Group | 0.02 | 0 | 0 | 0 | 0 | 0 |
| TBP-T | Tetra Bio Pharma | 0.03 | 0 | 0 | 0 | 0 | 0 |
| BSX-T | Belo Sun Mining | 0.08 | 0 | 0 | 0 | 0 | 0 |
| VQS-T | VIQ Solutions | 0.47 | 0 | 0 | 0 | 0 | 0 |
| VIVO-T | VIVO Cannabis | 0.03 | 0 | 0 | 0 | 0 | 0 |
| ADCO-T | Adcore | 0.27 | 0 | 0 | 0 | 0 | 0 |
| LSPK-T | LifeSpeak | 0.86 | 0 | 0 | 0 | 0 | 0 |
More about Antibe Therapeutics
Stocks in this category are held primarily for capital appreciation. Nano, micro, and small cap stocks can be very volatile and may generate high returns or losses. Whereas mid and large cap stocks tend to be more stable.
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
